Tech Company Financing Transactions

Edgewise Therapeutics Funding Round

Edgewise Therapeutics closed a $50 million Series B funding round on 9/18/2019. Investors included Novo Ventures, U.S. Venture Partners and CureDuchenne Ventures.

Transaction Overview

Company Name
Edgewise Therapeutics
Announced On
9/18/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors

Novo Ventures (Lead Investor) (Kenneth Harrison)

U.S. Venture Partners (Lead Investor) (Jonathan Root)

CureDuchenne Ventures

Deerfield Capital (Robert Jackson)

New Leaf Venture Partners

OrbiMed

Proceeds Purpose
The financing will support the advancement of Edgewise Therapeutic's lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company's pipeline.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3415 Colorado Ave.
Boulder, CO 80304
USA
Phone
(303) 735-8373
Website
www.edgewisetx.com
Email Address
[email protected]
Overview
Edgewise Therapeutics is a new company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury.
Profile
Edgewise Therapeutics LinkedIn Company Profile
Social Media
Edgewise Therapeutics Company Twitter Account
Company News
Edgewise Therapeutics News
Facebook
Edgewise Therapeutics on Facebook
YouTube
Edgewise Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kevin Koch
  Kevin Koch LinkedIn Profile  Kevin Koch Twitter Account  Kevin Koch News  Kevin Koch on Facebook
Chief Financial Officer
Michael Carruthers
  Michael Carruthers LinkedIn Profile  Michael Carruthers Twitter Account  Michael Carruthers News  Michael Carruthers on Facebook
Chief Medical Officer
Kirsten Gruis
  Kirsten Gruis LinkedIn Profile  Kirsten Gruis Twitter Account  Kirsten Gruis News  Kirsten Gruis on Facebook
Chief Scientific Officer
Alan Russell
  Alan Russell LinkedIn Profile  Alan Russell Twitter Account  Alan Russell News  Alan Russell on Facebook
Vice President
Abby Bronson
  Abby Bronson LinkedIn Profile  Abby Bronson Twitter Account  Abby Bronson News  Abby Bronson on Facebook
VP - Bus. Development
Behrad Derakhshan
  Behrad Derakhshan LinkedIn Profile  Behrad Derakhshan Twitter Account  Behrad Derakhshan News  Behrad Derakhshan on Facebook
VP - General Counsel
John Moore
  John Moore LinkedIn Profile  John Moore Twitter Account  John Moore News  John Moore on Facebook
VP - Regulatory Affairs
Nicole Kilburn
  Nicole Kilburn LinkedIn Profile  Nicole Kilburn Twitter Account  Nicole Kilburn News  Nicole Kilburn on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/18/2019: Vic.ai venture capital transaction
Next: 9/18/2019: Kaia Health venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.